3 Ways to Cash In on the Multiplex Turnaround No One Saw Coming

AMC reported Q3 revenue up 32% year over year to $1.7 billion, adjusted EPS of $0.13 versus a year-ago loss, and nearly tripled adjusted EBITDA; year-to-date revenue rose 22%. IMAX shares are up 40% in 2026 and the article cites forecasts for revenue growth of 19% to nearly $500 million and adjusted earnings growth of 56%. EPR Properties has returned 20% this year and yields 6.1%, while movie theaters account for 34% of its annualized base rent; the article notes its exposure to economic slowdowns and higher interest rates.

Analysis

The recovery is more investable as a content-and-format thesis than as a blanket theater-equity call. A stronger slate can improve premium-screen utilization and give studios more reason to preserve theatrical windows; IMAX may capture disproportionate value if audiences trade up for event films. But blockbuster concentration cuts both ways: a few delayed or weak tentpoles can quickly reverse attendance expectations, while Cinemark and other exhibitors also compete for the same releases and premium-format allocation.

AMC’s operating rebound does not automatically translate into comparable per-share value creation. Prior dilution means revenue and EBITDA growth can coexist with weaker equity participation, and adjusted profitability should be checked against cash generation, interest burden, and share count. EPR adds a different exposure: theater recovery supports rent coverage, but tenant concentration and higher refinancing costs can overwhelm the 6.1% yield if rates stay elevated or a major exhibitor weakens. The article supplies no valuation, leverage, or cash-flow detail sufficient to call any of the three cheap.

Near term, sentiment and slate optimism may support the group, but much of the easy re-rating may already be reflected after the reported share gains. Over 1–3 months, verify AMC cash flow/share count and IMAX bookings or guidance revisions. Over 6–18 months, the key test is whether studios sustain theatrical windows and attendance beyond a small number of franchise releases. A recession, weaker film slate, renewed dilution, or adverse rate move would challenge the thesis.

Key Decisions for Investors

• Prefer IMAX over broad exhibitor exposure, but avoid chasing the sharp run-up. Consider staged entry only if upcoming bookings and guidance confirm that premium-format demand is extending beyond a handful of tentpoles; falsify on downward guidance revisions or weakening bookings.
• Treat AMC as a high-volatility operating recovery, not a clean earnings-compounding story. Before adding, verify operating cash flow, net debt/interest burden, and diluted share-count trends; persistent dilution or EBITDA growth failing to convert to cash would invalidate the equity thesis.
• Keep EPR on an income watchlist rather than buying solely for yield. Track theater-tenant rent coverage, debt maturities/refinancing costs, and dividend coverage; reassess if tenant stress rises or rates push financing conditions materially tighter.
• No forced sector-wide long: if theater exposure is desired, a small IMAX-over-exhibitors relative position is more defensible than an AMC-led basket, subject to valuation and borrow/liquidity checks. Avoid an outright AMC short without a catalyst given meme-driven volatility.